20-O-β-D-吡喃葡萄糖苷-20(S)-原人参二醇对抗肝癌药物的增敏作用研究

Sensitization of 20-O-β-D-glucopyranoside-20(S)-protopanaxadiol on chemotherapy in patients with hepatocellular carcinoma

目的探讨20-O-β-D-吡喃葡萄糖苷-20(S)-原人参二醇(人参皂苷IH901)与医学上常用抗肝癌药物环磷酰胺(CTX)、5-氟尿嘧啶(5-FU)、顺铂(cDDP)单独用药及联合用药体外抗肝癌细胞Bel-7402、SMMC-7721的活性。方法应用MTT法检测人参皂苷IH901、CTX、5-FU、cDDP分别在不同质量浓度下单独及联合用药对肝癌细胞的增殖抑制率,并根据金氏公式计算其协同指数(Q值),进而评价两药联用的增敏效果。结果 IH901与CTX联合用药后对Bel-7402、SMMC-7721抑制作用明显增强,且二者合用具有协同作用;而IH901与5-FU联合用药后对2种细胞仅相加效果;IH901与cDDP联合用药,对Bel-7402仍然是相加的效果,对SMMC-7721则是具有轻微的协同效果。结论人参皂苷IH901可增强CTX对肝癌细胞增殖的抑制作用,具有化疗协同效果,且具有一定的广谱性,可能成为一种潜在的抗肝癌药物。

Objective In order to investigate the sensitization of 20-O-β-D-glucopyranoside-20（S）-protopanaxadiol（ginsenoside IH901） with several common drugs CTX,5-FU, cDDP in hepatocellular carcinoma（HCC） Bel-7402 and SMMC-7721.Methods The inhibitory rates on HCC in IH901,CTX,5-FU,cDDP, IH901 with CTX,IH901 with 5-FU,and IH901 with cDDP groups were detected by MTT assay.The synergism index,Q value,was calculated to judge the sensitization of combined drugs.Results The IH901 with CTX group could increase the inhibitory effect on cell proliferation of HCC significantly with the synergistic effect.The inhibitory rate in IH901 with 5-FU group was just superposition on two cell lines.IH901 with cDDP group was still superposition on Bel-7402,but lightly had the synergistic effect on SMMC-7721.Conclusion The IH901 could increase the inhibitory effect of CTX on cell proliferation of HCC and the sensitizasion on chemotherapy and also have wide adaptability.